We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-0.98%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$303M
AUM Growth
-$17.4M
Cap. Flow
-$10.2M
Cap. Flow %
-3.35%
Top 10 Hldgs %
82.65%
Holding
26
New
4
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$12.2M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$4.62M
3
TMBR
Timber Pharmaceuticals, Inc.
TMBR
+$4.37M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.78M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.99M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$23.1M
2
RGNX icon
Regenxbio
RGNX
+$9.32M
3
AGRX
Agile Therapeutics
AGRX
+$3.55M
4
PTN
Palatin Technologies
PTN
+$148K
5
KALV
KalVista Pharmaceuticals
KALV
+$7

Sector Composition

Rank Sector Weight
1 Healthcare 91.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTN
26
Palatin Technologies
PTN
$13.7M
– –
-188
Closed -$148K
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Vivo Capital held 26 positions worth $303M, down 5.4% from $321M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Vivo Capital withdrew a net $10.2M in Q4 2016, closing 1 position and reducing 4 holdings. Its most notable exit was Palatin Technologies, an estimated $148K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

Against the trend, Vivo Capital opened a new position in Strongbridge Biopharma plc. worth $7.2M.

  • Vivo Capital's largest Q4 2016 buy was Strongbridge Biopharma plc.: 3,000,000 shares worth $7.2M.
  • Vivo Capital added most to Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2016, an estimated $4.62M increase.
  • Vivo Capital's biggest Q4 2016 reduction was Aclaris Therapeutics, cutting an estimated $23.1M.
  • Vivo Capital fully exited Palatin Technologies in Q4 2016, selling an estimated $148K.
  • Vivo Capital's ten largest holdings make up 83% of its $303M portfolio in Q4 2016.
  • Vivo Capital opened 4 new positions and closed 1 in Q4 2016.
  • Vivo Capital's portfolio value fell 5.4% quarter-over-quarter to $303M.

Based on Vivo Capital's 13F filing for Q4 2016, filed 14 Feb 2017.